Table 3.

Analysis of LTAD Effects on Trial Endpoints among Patients with Gleason Score 8–10 and N0/NX

	Total Events		Unadjusted 15-year Estimate (% Event-free) (95% Confidence Interval)		Adjusted Hazard Ratio*
Outcome	STAD	LDAT	STAD	LDAT	LDAT/STA D HR	95% CI	p
Disease progression endpoints
Disease-free Survival	162	152	5.2	9.9	0.64	0.51 – 0.81	< 0.0001
			2.4 – 9.6	5.8 – 15.4
Local Progression	47	29	72.9	82.3	0.57	0.35 – 0.91	0.02
			66.0 – 79.4	76.1 – 87.7
Distant metastasis	72	43	57.0	74.3	0.53	0.36 – 0.77	<0.0001
			49.5 – 64.7	67.3 – 80.8
Biochemical failure	117	84	30.9	48.3	0.52	0.39 – 0.69	<0.0001
			24.4 – 38.6	40.8 – 56.5
Mortality endpoints
Disease-specific survival	63	40	62.2	75.6	0.54	0.36 – 0.81	0.003
			54.6 – 69.7	68.5 – 82.1
Other cause of death	80	99	54.8	45.8	0.87	0.64 – 1.19	0.39
			47.1 – 62.7	38.2 -- 54.1
Overall survival	143	139	16.9	21.4	0.75	0.59 – 0.95	0.02
			11.4 – 23.4	15.1 – 28.3

^*Adjusted HR from Cox proportional hazard models including the following covariates: PSA (≤30, >30 ng/mL), T stage (T2, T3, T4), N stage (N0/NX, N1/N2), Gleason score (8–10, < 8), age, and treatment (STAD+RT,LTAD+RT)